Holen Sie sich die Stockscreener-App
64.04
1.83%
1.15
Handel nachbörslich:
63.90
-0.14
-0.22%
Halozyme Therapeutics Inc Aktie (HALO) Neueste Nachrichten
Halozyme up after guidance raise, Morgan Stanley upgrade - MSN
H.C. Wainwright Lifts PT on Halozyme Therapeutics (HALO) to $75 From $72 - MSN
Here’s Why Halozyme Therapeutics (HALO) Traded Town in Q2 - Insider Monkey
Halozyme stock price target raised to $56 by Goldman Sachs on IRA impact analysis - Investing.com Canada
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term - sharewise.com
Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $63.00 at JPMorgan Chase & Co. - MarketBeat
J&J, Halozyme cut at Leerink on price control risk for combo products - MSN
Is Halozyme Therapeutics Inc. part of any ETF3x Gain Trade Candidates - thegnnews.com
HALO Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View - MSN
Leerink Partners Maintains Sell Rating on Halozyme with $51 Price Target - AInvest
After Golden Cross, Halozyme Therapeutics (HALO)'s Technical Outlook is Bright - Yahoo Finance
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock - Yahoo Finance
Why Have Halozyme Stocks Plummeted? - TipRanks
What Does the Market Think About Halozyme Therapeutics? - 富途牛牛
A Quick Look at Today's Ratings for Halozyme Therapeutics(HALO.US), With a Forecast Between $75 to $91 - 富途牛牛
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q2 2025 Earnings Call Transcript - Insider Monkey
Results: Halozyme Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - 富途牛牛
HC Wainwright Raises Price Target for Halozyme Therapeutics to $75 - AInvest
Halozyme raises 2025 revenue guidance to $1.355B amid accelerating royalty growth and new product catalysts - MSN
Halozyme Therapeutics’ Earnings Call Highlights Robust Growth - TipRanks
Halozyme Therapeutics Surges on 86.74% Volume Spike to $360M, 329th Market Activity as Royalty Revenue Drives 41% EBITDA Jump - AInvest
Halozyme Therapeutics 2025 Q2 Earnings Surpasses Expectations, Net Income Surges 77% - AInvest
Halozyme Therapeutics (HALO): A High-Conviction Buy as Royalty-Driven Growth Accelerates - AInvest
Halozyme Therapeutics Lifts Outlook As Royalties Climb Higher - Finimize
Halozyme (HALO) Surges on Upgraded Guidance and Increased Revenue - GuruFocus
HALO: JMP Securities Raises Price Target Despite Maintaining "Ma - GuruFocus
Halozyme up after guidance raise, Morgan Stanley upgrade (HALO) - Seeking Alpha
Halozyme Therapeutics: JMP Securities Raises PT to $91 from $78, Maintains Market Outperform - AInvest
Halozyme Therapeutics Guidance Upgrade Driven by Robust Royalty Revenue, Morgan Stanley Says - MarketScreener
HALO Analyst Rating: HC Wainwright Maintains 'Buy' and Raises Pr - GuruFocus
Morgan Stanley Upgrades Halozyme Therapeutics (HALO) to Overweig - GuruFocus
Halozyme Therapeutics 2025 Q2 Earnings Surpasses Expectations with Net Income Jumping 77.1% - AInvest
Morgan Stanley Upgrades Halozyme Therapeutics to Overweight From Equalweight, Raises Price Target to $75 From $62 - MarketScreener
Halozyme Sees Price Target Boost Amid Strong Q2 Performance: Analyst Increases Target to $75, Maintains Buy Rating - AInvest
Halozyme (HALO) Sees Price Target Boost Amid Strong Q2 Performan - GuruFocus
Halozyme Therapeutics: A Masterclass in Platform-Driven Royalty Growth and Strategic Scalability - AInvest
Halozyme Therapeutics Reports Strong Q2 Earnings, Surpassing ExpectationsNews and Statistics - IndexBox
Halozyme Therapeutics: A High-Conviction Buy in the IP-Driven Biotech Revolution - AInvest
Halozyme (HALO) Reports Record Q2 Revenue and Boosts 2025 Guidan - GuruFocus
Halozyme's Q2 2025: Unpacking Contradictions in Patent Litigation, ENHANZE Impact, and Regulatory Challenges - AInvest
Why Halozyme Shares Are Moving Amid Strong Earnings - TipRanks
Halozyme (HALO) Receives Upgrade and Raised Price Target from Mo - GuruFocus
Halozyme Therapeutics stock price target raised to $91 by Citizens JMP - Investing.com Australia
Morgan Stanley upgrades Halozyme stock to Overweight on ORPHAN Cures Act - Investing.com Nigeria
Morgan Stanley upgrades Halozyme stock to Overweight on ORPHAN Cures Act By Investing.com - Investing.com South Africa
Halozyme Therapeutics: Q2 Earnings Snapshot - New Haven Register
Halozyme Therapeutics Inc (HALO) Q2 2025 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance
Halozyme Therapeutics Inc (HALO) Q2 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Initiatives - GuruFocus
Halozyme Therapeutics Inc (HALO) Q2 2025 Earnings Call Highlights: Record Revenue Growth and ... By GuruFocus - Investing.com Canada
Halozyme Therapeutics Reports Strong Q2 2025 Results - TipRanks
0.91%
3.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):